Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 18328585.
- Also identified by DOI 10.1016/j.radonc.2008.01.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amifostine is an organic thiophosphate prodrug used for cytoprotection against toxic effects of radiotherapy and chemotherapy. In a European prospective study of SJS/TEN, six patients were suspected to have SJS/TEN associated with amifostine. Our findings suggest that the risk of life-threatening cutaneous adverse reactions to amifostine could be significantly increased.
Medical subject headings
- Amifostine
- Head and Neck Neoplasms
- Radiation-Protective Agents
- Stevens-Johnson Syndrome